SCHEMBL515928

SCHEMBL515928

O=C(Cl)OC(=O)CC/C(=N/O)OC(=O)Cl

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509780 0.81 ALDH1A1 (0.43) ALDH1A1
SCHEMBL942008 0.77 ALDH1A1 (0.34) ALDH1A1
SCHEMBL238158 0.76 ALDH1A1 (0.32) ALDH1A1
SCHEMBL5968591 0.74 EGLN1 (0.39) ALDH1A1
SCHEMBL5785545 0.74 ALDH1A1 (0.38) ALDH1A1
SCHEMBL731664 0.74 ALDH1A1 (0.46) ALDH1A1
SCHEMBL705151 0.74 ALDH1A1 (0.31) ALDH1A1
SCHEMBL1768486 0.72 ALDH1A1 (0.34) ALDH1A1
SCHEMBL781568 0.72 ALDH1A1 (0.34) ALDH1A1
SCHEMBL733088 0.72 ALDH1A1 (0.62) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381259-A1 Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof PFIZER (US) 2025-12-18 US claimed
EP-4661911-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Pfizer Inc. (US) 2025-12-17 EP claimed
WO-2025133971-A1 IMPROVED METHODS FOR PRODUCING BACTERIAL CAPSULAR SACCHARIDE GLYCOCONJUGATES PFIZER INC. (US) 2025-06-26 WO claimed
CN-119978237-A Responsive elastomeric polymers and methods of making and using the same 珀杜研究基金会 2025-05-13 CN claimed
EP-4463186-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Pfizer Inc. (US) 2024-11-20 EP claimed
CN-118510548-A Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 辉瑞公司 2024-08-16 CN claimed
US-20240271085-A1 ACTIVATED DISSOLVABLE SUPPORTS FOR AFFINITY BINDING AND CELL CULTURE CORNING INCORPORATED 2024-08-15 US claimed
WO-2024166008-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF PFIZER INC. (US) 2024-08-15 WO claimed
EP-4346892-A2 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Pfizer Inc. (US) 2024-04-10 EP claimed
CN-117729933-A Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 辉瑞公司 2024-03-19 CN claimed
EP-2078197-B1 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MED SYST INC (US) 2016-03-23 EP claimed
US-20140161877-A1 PEDERIN AND PSYMBERIN AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-06-12 US claimed
EP-2444807-B1 MONO- AND DINITROPYRAZOLE HAPTEN CONJUGATES VENTANA MED SYST INC (US) 2014-06-11 EP claimed
US-20130005660-A1 Plasma Activation of Biological Materials for Surface Modification ORTHOBOND, INC. (US) 2013-01-03 US claimed
US-20120294953-A1 Surface Modified Biological Materials ORTHOBOND, INC. (US) 2012-11-22 US claimed
WO-2012149330-A1 SURFACE MODIFIED BIOLOGICAL MATERIALS ORTHOBOND, INC. (US) 2012-11-01 WO claimed
WO-2012149366-A1 PLASMA ACTIVATION OF BIOLOGICAL MATERIALS FOR SURFACE MODIFICATION ORTHOBOND, INC. (US) 2012-11-01 WO claimed
EP-2444807-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2012-04-25 EP claimed
EP-2275085-A1 Biodegradable copolymer suitable for delivering nucleic acid materials into cells University of Rostock (DE) 2011-01-19 EP claimed
US-20040185564-A1 Biodegradable copolymers containing polyethylenimine that are capable of complexing with nucleic acid and serving as tools for gene transfer; gene therapy AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2004-09-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140161877-A1 PEDERIN AND PSYMBERIN AGENTS PRSS12, CCL2, APLNR ALDH1A1 3928/4885
US-20250381259-A1 Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof CD44, CD47, FUT5 ALDH1A1 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.